THAR

Tharimmune Inc.

NASDAQ: THAR · HEALTHCARE · BIOTECHNOLOGY

$3.19

+0.00% today

Updated 2026-06-04

Market cap

$177.09M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.68

Dividend yield

—

52W range

$1 – $9

Volume

0.6M

Market cap

$177.09M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.68

Dividend yield

—

52W range

$1 – $9

Volume

0.6M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.0

Quality

C+

3.0

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$5.00

+56.74%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

Price chart

Stock snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-1.86M

Key financials

Revenue Net Income Free Cash Flow

Metric	2021	2022	2023	2024	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-2.21M	$-8.47M	$-9.32M	$-12.20M	$-2.10M
EPS	—	—	—	—	$-3.68
Free cash flow	$-1.09M	$-6.56M	$-7.30M	$-10.90M	$-1.86M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
THAR	$177.09M	17	4.3	3.0	5.0	5.0	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Tharimmune Inc. trades at $3.19. Our Smart Value Score of 17/100 indicates the stock is weak.

Frequently asked questions

What is Tharimmune Inc.'s stock price?

Tharimmune Inc. (THAR) trades at $3.19.

Is Tharimmune Inc. overvalued?

Tharimmune Inc. carries a Smart Value Score of 17/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Tharimmune Inc. (THAR)?

The 12-month analyst consensus target is $5.00, about 56.7% above the current $3.19. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-2.25%

Beta1.45

50D MA$3.23

200D MA$2.60

Shares out0.04B

Float0.03B

Short ratio—

Avg volume0.6M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

THAR vs LLY →THAR vs JNJ →THAR vs ABBV →Stock screener →